X

Trial Profile

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics
Acronyms Meld-ATG

Most Recent Events

03 Oct 2024 This trial has been completed in Slovenia, according to European Clinical Trials Database
03 Jan 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
03 Jan 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com